Navigation Links
China Biologic Products Announces One of Its R&D Projects Has Been Listed In National Torch Plan

TAIAN CITY, China, March 25 /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("CBP," or "the Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that one of its R&D projects, "High-concentration Human Hepatitis B Immunoglobulin", was listed in the National Torch Plan of China.

The National Torch Plan was organized and executed by The Ministry of Science and Technology of the People's Republic of China in 1988, with its objective to encourage innovation and promote the development of China's high- tech industry. For those projects and enterprises listed in the plan, the central and local government provides a series of support programs, such as favorable tax treatment, innovation protection, technical support, and a friendly business environment.

"We are pleased with this project's acceptance into the National Torch Plan, which is a strong endorsement of our strategy to focus on research and development of more technologically advanced plasma based products," said Mr. Stanley Wong, CEO of China Biologic. "It should also have a very positive impact on our application to be considered one of China's National High-Tech Enterprises. We expect that this continued support from the government will provide us with a competitive advantage for our manufacturing technology and our products in the marketplace."

About China Biologic Products, Inc.

Through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., China Biologic Products, Inc. (the "Company"), is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention diseases.

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the ability of the Company to expand its list of potential investors and increase its liquidity and visibility in the market or otherwise achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Company Contact:

Mr. Stanley Wong


China Biologic Products, Inc.

Tel: +86-538-6202306


Investor Relations Contact:

Mr. Crocker Coulson


CCG Elite Investor Relations

Tel: +1-646-213-1915 (NY office)


SOURCE China Biologic Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lucids VivaScope(R) Reflective Confocal Microscope Approved for Sale in China
2. China Aoxing Pharmaceutical Company Signed Definitive Acquisition Agreement to Acquire Shijiazhuang Lerentang Pharmaceutical Company, Ltd.
3. Pharmaxis First Steps into China
4. Hovione Buys Drug Manufacturing Facility in China
5. China Nepstar Chain Drugstore to Acquire 18 Stores from Dongguan Hui Ren Tang Pharmaceutical Co.
6. China Yingxia International Announces Q4 and FY 2007 Estimates
7. China Biologic Products Commences Trading on OTC Bulletin Board
8. STAAR Surgical Receives Approval to Market Visian(R) Toric Implantable Collamer Lens in China
9. China Technology Appoints Deloitte Touche Tohmatsu CPA as Independent Auditor
10. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
11. China Shenghuo to Market 12Ways(R) Skin Care Products in the U.S. through Agreement with Home Shopping Group
Post Your Comments:
(Date:6/27/2016)... 27, 2016  Alex,s Lemonade Stand Foundation (ALSF), a ... will open a state-of-the-art bioinformatics lab, using ,big data, ... announcement comes as Liz Scott , co-executive director ... Moonshot Summit in Washington, D.C. , ... participant and advocate of pediatric cancer research and awareness. ...
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... 2016  Sequenom, Inc. (NASDAQ: SQNM ), ... through the development of innovative products and services, announced ... United States denied its petition to review ... Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are not ... the Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
Breaking Biology News(10 mins):